Shares in SuperGen Slide
After Pulling Orathecin NDA

By

Judy Lam Dow Jones Newswires

Updated Jan. 3, 2005 7:06 p.m. ET

NEW YORK -- Shares of SuperGen Inc. plunged as much as 16% after the company withdrew its New Drug Application for Orathecin, citing the lack of data to support the drug's approval as a single-agent treatment for pancreatic cancer.

Earlier Monday, the Dublin, Calif., drug company said its decision to pull the filing was based on discussions with both the Food and Drug Administration and consultants helping the company on its Orathecin...